Ultra Nasdaq Biotechnology - BIB Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the NASDAQ Biotechnology Index®.

This Ultra ProShares ETF seeks a return that is 2x the return of an index or other benchmark (target) for a single day, as measured from one NAV calculation to the next. Due to the compounding of daily returns, ProShares' returns over periods other than one day will likely differ in amount and possibly direction from the target return for the same period. These effects may be more pronounced in funds with larger or inverse multiples and in funds with volatile benchmarks. Investors should monitor their holdings consistent with their strategies, as frequently as daily. For more on correlation, leverage and other risks, please read the prospectus.

  • Considerations for Geared Investing – Learn More

Index/Benchmark Summary

The NASDAQ Biotechnology Index is a modified capitalization weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical. The securities also meet other eligibility criteria determined by The NASDAQ OMX Group, Inc., including minimum market capitalization and liquidity requirements.

Fundamentals as of 12/29/17

Total Number of Companies 198
Price/Earnings Ratio 121.30
Price/Book Ratio 5.01
Dividend Yield *(%) 0.48
Average Index Market Capitalization $4.78 billion

* Derivative contracts are priced to reflect the underlying index yield and will not generate dividend income. Because ProShares invest in derivatives, they will not have dividend distributions that reflect those of their applicable indexes.

Index Holdings Information as of 12/29/17

Top 10 Index Companies Weight
Celgene Corp. 8.15%
Biogen Inc. 7.79%
Amgen Inc. 7.79%
Gilead Sciences Inc. 7.54%
Regeneron Pharmaceuticals Inc. 5.29%
Vertex Pharmaceuticals Inc. 4.09%
Illumina Inc. 3.74%
Alexion Pharmaceuticals Inc. 3.66%
Mylan NV 3.11%
Incyte Corp. 2.74%

ProShares may invest in financial instruments (including derivatives) that, in combination, should have similar daily price return characteristics to the fund's benchmark.

Index Sector Weightings § Weight
Biotechnology 81.83%
Pharmaceuticals 10.63%
Life Sciences Tools & Services 7.16%
Health Care Equipment & Supplies 0.30%
Health Care Technology 0.05%
Health Care Providers & Services 0.04%

§ Sum of weightings may not equal 100% due to rounding.